Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Amyotrophic Lateral Sclerosis (ALS)
Clinical Trial
NCT00444613Last updated: 12/4/2025
4523.T
Eisai Co., Ltd.